Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
X-ACT: Omalizumab in Chronic Spontaneous Urticaria and Angioedema
NCT01723072Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2013
- Primary completion
- May 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic spontaneous urticaria (CSU) and angioedema comparing Omalizumab with Placebo (2 arms). Primary endpoint: Chronic Urticaria Quality of Life Questionnaire Total Score at 28 weeks. Started Jan 2013; status: completed.
02
Drugs
omalizumab
03
Conditions
chronic spontaneous urticaria (CSU)angioedema
Beyond the preview
Go deeper on NCT01723072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01723072.